The question is narrower than it sounds

Chronic pain includes neuropathic, musculoskeletal, inflammatory, cancer-related, and other conditions. Trials also study different THC-to-CBD ratios, synthetic cannabinoids, routes, durations, and outcomes. Combining them under one label can hide clinically important differences.

The 2025 AHRQ living review focuses on comparative studies lasting at least four weeks. Its framework separates formulation types and evaluates both benefit and harm rather than treating cannabis as one intervention.

What the reviews suggest

For selected adults and selected formulations, reviews have found small short-term improvements in pain or function. Dizziness, sedation, and nausea can increase, and evidence about longer-term benefit, dependence, withdrawal, and serious harms remains limited.

A statistically detectable average difference may still be smaller than the change an individual considers worthwhile. Results from regulated trial products should not be generalized to products with unknown composition.

How to use this evidence

This evidence does not establish cannabis as a universal substitute for established pain care. A clinician can consider the pain diagnosis, other treatments, medicines, mental-health history, driving and workplace risks, and the law that applies to the patient.

Why the type of pain matters

Nerve pain, arthritis, back pain, cancer-related pain, headache, and widespread pain can arise through different mechanisms. A product that changes one outcome in one group should not be presented as a treatment for all chronic pain.

Trials also use different measures: pain intensity, physical function, sleep, quality of life, or the number of people reaching a chosen level of improvement. A small change on a rating scale may not translate into a noticeable return to daily activities.

What living reviews find

The AHRQ living review groups evidence by product type rather than treating cannabis as one intervention. For selected adults and selected THC-containing formulations, it has found small short-term changes in pain or function. Evidence for some other products remains insufficient.

Dizziness, sedation, and nausea can increase. Trial participants, regulated products, and follow-up periods may differ from people using retail products over years, so the findings have clear boundaries.

Questions that remain after a positive result

A useful decision requires more than asking whether average pain decreased. Did function improve? How many people stopped because of adverse effects? Was benefit maintained? Did tolerance or withdrawal emerge? How did the treatment compare with other options rather than only with placebo?

Many trials are too short to answer those questions fully. Evidence gaps are especially important for frequent, sustained exposure and for people with complex medical histories or multiple medicines.

Putting the evidence in clinical context

Cannabinoids should not be described as a universal substitute for established pain care. The diagnosis, treatment goals, prior therapies, mental-health and substance-use history, medicines, driving, work, and local law can all affect the balance of benefit and harm.

A clinician can help define a meaningful goal and decide how response and adverse effects would be assessed. This page explains the evidence and its limits; it does not recommend a product or provide instructions for use.